0001209191-21-029064.txt : 20210429
0001209191-21-029064.hdr.sgml : 20210429
20210429174623
ACCESSION NUMBER: 0001209191-21-029064
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210427
FILED AS OF DATE: 20210429
DATE AS OF CHANGE: 20210429
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GADICKE ANSBERT
CENTRAL INDEX KEY: 0001134655
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38800
FILM NUMBER: 21872483
MAIL ADDRESS:
STREET 1: THE JOHN HANCOCK TOWER
STREET 2: 200 CLARENDON STREET, 54TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM Oncology Impact Management LP
CENTRAL INDEX KEY: 0001687078
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38800
FILM NUMBER: 21872481
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 6174259200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Oncology Impact Fund (Cayman) Management L.P.
CENTRAL INDEX KEY: 0001721036
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38800
FILM NUMBER: 21872482
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 6174259200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: UBS Oncology Impact Fund L.P.
CENTRAL INDEX KEY: 0001691428
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38800
FILM NUMBER: 21872479
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM Oncology Impact Management GP LLC
CENTRAL INDEX KEY: 0001721035
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38800
FILM NUMBER: 21872480
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 6174259200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Harpoon Therapeutics, Inc.
CENTRAL INDEX KEY: 0001708493
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473458693
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 131 OYSTER POINT BOULEVARD
STREET 2: SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-443-7400
MAIL ADDRESS:
STREET 1: 131 OYSTER POINT BOULEVARD
STREET 2: SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-04-27
0
0001708493
Harpoon Therapeutics, Inc.
HARP
0001134655
GADICKE ANSBERT
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001721036
Oncology Impact Fund (Cayman) Management L.P.
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001687078
MPM Oncology Impact Management LP
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001721035
MPM Oncology Impact Management GP LLC
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001691428
UBS Oncology Impact Fund L.P.
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
Common Stock
2021-04-27
4
S
0
3501
20.99
D
7016619
I
See Footnote
Common Stock
2021-04-27
4
S
0
8328
21.26
D
7008291
I
See Footnote
Common Stock
2021-04-28
4
S
0
14219
21.64
D
6994072
I
See Footnote
Common Stock
2021-04-28
4
S
0
36803
22.01
D
6957269
I
See Footnote
Common Stock
2021-04-29
4
S
0
45511
22.02
D
6911758
I
See Footnote
Common Stock
2021-04-29
4
S
0
21781
22.54
D
6889977
I
See Footnote
Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021.
The shares were sold as follows: 3,077 by UBS Oncology Impact Fund, L.P. ("UBS Oncology") and 424 by MPM Asset Management LLC ("AM LLC").
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.08 to $21.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. ("BV 2014"), 152,470 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 96,376 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 308,773 by AM LLC and 3,801,903 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The shares were sold as follows: 7,320 by UBS Oncology and 1,008 by AM LLC.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.08 to $21.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 307,765 by AM LLC and 3,794,583 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The shares were sold as follows: 12,498 by UBS Oncology and 1,721 by AM LLC.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.92 to $21.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 306,044 by AM LLC and 3,782,085 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The shares were sold as follows: 32,349 by UBS Oncology and 4,454 by AM LLC.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.93 to $22.155 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 301,590 by AM LLC and 3,749,736 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The shares were sold as follows: 40,003 by UBS Oncology and 5,508 by AM LLC.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.32 to $22.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 296,082 by AM LLC and 3,709,733 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The shares were sold as follows: 19,145 by UBS Oncology and 2,636 by AM LLC.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.36 to $22.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 293,446 by AM LLC and 3,690,588 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
/s/ Ansbert Gadicke
2021-04-29
/s/ Ansbert Gadicke, managing member of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P.
2021-04-29
/s/ Ansbert Gadicke, managing member of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP
2021-04-29
/s/ Ansbert Gadicke, managing member of MPM Oncology Impact Management GP LLC
2021-04-29
/s/ Ansbert Gadicke, managing member of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P.
2021-04-29